Results for csl: 39

MELBOURNE, Aug 19 - Australian biotherapies group CSL Ltd <CSL.AX> expects to book sales of around A$300 million ($248 million) from swine flu vaccines in the year to June 2010, Chief Executive Brian McNamee said...

MELBOURNE, Aug 19 - Australian biotherapies group CSL Ltd <CSL.AX> reported a 63 percent rise in full year profit on Wednesday, boosted by sales growth in blood products and flu vaccines and currency gains. It...

ZTE Corp<000063><763>, a leading global provider of telecommunications equipment and network solutions in China, and Hong Kong's largest mobile operator CSL Ltd yesterday jointly launched the world's first SDR-based HSPA+ AII IP commercial network in Hong Kong, sources reported....

* H1N1 vaccine production at maximum capacity * Shrugs off any plasma oversupply * Shares up 1.6 percent (Adds CEO comments) MELBOURNE, Oct 14 - Australian blood products and vaccines maker CSL Ltd <CSL.AX> warned...

MELBOURNE, Oct 14 - Australian blood products and vaccines maker CSL Ltd <CSL.AX> maintained its full year profit forecast on Wednesday, and said first-quarter trading was in line with its expectations. However in reaffirming its...

WASHINGTON, Sept 10 - CSL Ltd said on Thursday a single dose of its H1N1 swine flu vaccine would protect adults against the virus, a finding that means vaccine supplies can be stretched further than...

ZTE Corp<000063><0763>, a leading global provider of telecom equipment and network solutions in China, recently formed a partnership with CSL Ltd<CSL> to build a 4G commercial trial network in Hong Kong.The two companies will jointly expand CSL's next generation network capabilities with the roll-out of...

MELBOURNE, Aug 19 - Shares in Australian biotherapies group CSL Ltd <CSL.AX> rose 3 percent after it beat market expectations with a 63 percent rise in full year profit and gave an upbeat forecast [ID:nSYD470662]....

SYDNEY, June 9 - Australian stocks edged up 0.2 percent on Tuesday, helped by banks, while blood plasma group CSL Ltd <CSL.AX> firmed after announcing a share buy back. The benchmark S&P/ASX 200 index <.AXJO>...

SYDNEY, June 9 - Australian blood products group CSL Ltd <CSL.AX> will return up to around A$1.6 billion ($1.26 billion) to shareholders through on-market share buybacks after aborting its planned takeover of U.S. rival Talecris...